【帖子标题】：My First Equity Research Report on Haleon (HLN) - BUY Rating, $11.50 PT. Tear it apart. 【帖子标题】：关于Haleon(HLN)的首份股票研究报告——买入评级，目标价11.5美元。请犀利指正。

【帖子正文】： I’m learning equity research and decided to make Haleon my first proper deep dive. I’ve tried to approach it like an actual institutional-style report: investment thesis, five-year financials, a DCF with defended assumptions, risk factors, catalysts, and, ultimately, a clear BUY/SELL call. 【帖子正文】：我正在学习股票研究，决定将Haleon作为首次深度分析对象。我尝试采用机构级报告的标准框架：投资论点、五年财务数据、附带论证假设的DCF模型、风险因素、催化剂，最终给出明确的买入/卖出建议。

I’ve also gone through the annual report, MD&A, risk factors, and notes to the accounts rather than just relying on the headline numbers. Basically, I tried to read the stuff people usually skip. 我不仅关注 headline 数据，还研读了年报、管理层讨论与分析、风险因素和财务报表附注——基本上就是那些人们通常会跳过的内容。

Now I’d really appreciate some brutal, honest feedback from people who actually know equity research. 现在，我真诚期待熟悉股票研究的人士给予犀利而真实的反馈。

A few things I’d specifically like you to tear apart: 特别希望你们重点批判以下几个方面：

Valuation I’m using a 7.5% WACC and 3% terminal growth. Are those assumptions actually defensible for Haleon, or am I being too aggressive/conservative? 估值：我采用7.5%的加权平均资本成本和3%的永续增长率。这些假设对Haleon是否合理？还是过于激进/保守？

Thesis Is there anything important I’m missing? Particularly risks, catalysts, or something that could fundamentally undermine the margin-expansion story? 论点：是否有重大遗漏？特别是可能从根本上破坏利润率提升逻辑的风险、催化剂或其他因素？

Structure Does the report resemble a proper equity research report, or is there too much unnecessary stuff and not enough of what actually matters? 结构：这份报告是否符合专业股票研究报告的范式？是否存在过多冗余内容而核心要素不足？

Data Do any of the numbers look suspicious or inconsistent? Are there particular figures or sources I should cross-check? 数据：是否有可疑或不一致的数字？哪些具体数据或来源需要交叉验证？

Overall quality What would I need to change to take this from “student learning equity research” to something that looks genuinely institution-ready? 整体质量：需要做哪些改进才能让这份报告从”学生习作”升级为”机构级”水平？

The basic thesis is: 核心投资论点是：

Haleon owns brands such as Sensodyne, Advil, Panadol and Centrum. Revenue growth has been relatively weak, but margins have expanded significantly, with operating margins around 22.5% and gross margins around 64.8%. FCF is around £2B annually, while net debt/EBITDA has been coming down toward 2.6x. Haleon旗下拥有舒适达(Sensodyne)、艾德维尔(Advil)、必理通(Panadol)和善存(Centrum)等品牌。虽然收入增长相对疲软，但利润率显著提升——营业利润率约22.5%，毛利率约64.8%。年度自由现金流约20亿英镑，净债务/EBITDA已降至2.6倍左右。

My argument is that the market is overly focused on the revenue growth miss versus management’s 4–6% medium-term target and is underappreciating the margin expansion, cash generation and potential H2 2026 recovery. 我认为市场过度关注收入增长未达管理层4-6%的中期目标，却低估了利润率扩张、现金流创造能力以及2026年下半年潜在的复苏机会。

My DCF gets me to roughly $11.50 versus a current price of about $9.70, so I’ve landed on BUY. 我的DCF估值显示目标价约11.5美元，相较当前约9.7美元的价格，故给出买入评级。

I’m still learning, so I’m much more interested in someone telling me where the analysis is wrong than telling me what I did well. 鉴于尚在学习阶段，相比赞美之词，我更希望听到对分析错误的指正。

Haleon_first_equity_report Haleon首份研究报告